Healio: Hematology and Oncology Today - Dr. Matthew Galsky: “PFS Correlated with OS in Urothelial Cancer”

 – June 18, 2013  –– 

Progression-free survival (PFS) at six and nine months predicted overall survival (OS) in a cohort of patients with metastatic urothelial carcinoma who were treated with first-line cisplatin-based chemotherapy, according to a study first published online May 29 in Cancer, a publication of the American Cancer Society. Lead author Matthew D. Galsky, MD, Director of Genitourinary Medical Oncology at the Icahn School of Medicine at Mount Sinai’s Tisch Cancer Institute, and colleagues suggested that six and nine month PFS could serve as endpoints in randomized phase two trials designed to screen the activity of novel regimens. Learn more